Articles

Potent preclinical activity of FLT3-directed chimeric antigen receptor T cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia

Children’s Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research; Philadelphia PA
Center for Cancer and Blood Disorders, Children's Hospital Colorado; Aurora, CO, USA; Department of Pediatrics, University of Colorado Anschutz Medical Campus; Aurora, CO
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda, MD
Children’s Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research; Philadelphia PA
Department of Pediatrics, University of Colorado Anschutz Medical Campus; Aurora, CO
Department of Pediatrics, University of Colorado Anschutz Medical Campus; Aurora, CO
Children’s Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research; Philadelphia, PA
Center for Cancer and Blood Disorders, Children's Hospital Colorado; Aurora, CO, USA; Department of Pediatrics, University of Colorado Anschutz Medical Campus; Aurora, CO
Children’s Hospital of Philadelphia, Division of Oncology and Center for Childhood Cancer Research; Philadelphia PA, USA; University of Pennsylvania Perelman School of Medicine and Abramson Cancer Center; Philadelphia PA
Center for Cancer and Blood Disorders, Children's Hospital Colorado; Aurora, CO, USA; Department of Pediatrics, University of Colorado Anschutz Medical Campus; Aurora, CO
Haematologica Early view Aug 11, 2022 https://doi.org/10.3324/haematol.2022.281456